NCT07358715Recruiting
Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals
A Multimodal Liquid Biopsy-Based Assay as a Pre-Screening Test Before Low Dose CT Thorax (LDCT) to Streamline Lung Cancer Screening in High-Risk Individuals
Source: ClinicalTrials.gov · Last updated 22 Jan 2026
Brief summary (registry, in English)
This study evaluates the feasibility and cost-effectiveness of using a blood-based liquid biopsy assay as a pre-screening tool before low-dose CT (LDCT) for lung cancer screening. By identifying individuals unlikely to have lung cancer, this approach aims to reduce unnecessary LDCT scans, radiation exposure, and healthcare costs, while improving early detection, particularly among high-risk individuals including never-smokers with a family history of lung cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- First submitted
- 6 Jan 2026
- Start date
- 1 Nov 2024
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- National University Hospital, Singapore
- Diseases
- Lung cancer
- NCT number
- NCT07358715
What you commit to
- Study type: Interventional
- Planned participants: 140
- From 1 Nov 2024 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior low-dose CT (LDCT), CT thorax, or PET-CT performed within 12 months prior to enrollment
- Lung Cancer Cohorts Only
Other illness
- Known allergy or contraindication to CT contrast agents
- Receipt of any prior cancer-directed treatment for lung cancer
Other
- Applicable to All Participants
- Pregnant or breastfeeding women
- Inability or unwillingness to comply with study procedures
- High-Risk Individuals Only
Who the study is looking for
- High-Risk Individuals (n = 100)
- No prior history of lung cancer
- Meets one of the following high-risk definitions:
- Current or former smoker (quit within the past 15 years), aged 55-74 years, with a smoking history of ≥30 pack-years; OR
- Never-smoker aged 55-75 years with a first-degree family history of lung cancer
- Able and willing to provide written informed consent
- Early-Stage Lung Cancer Patients (n = 20)
- Aged ≥21 years
- Histologically or clinically confirmed stage I-II lung cancer
- Treatment-naïve (no prior surgery, chemotherapy, radiotherapy, or immunotherapy for lung cancer)
- Able and willing to provide written informed consent
- Advanced-Stage Lung Cancer Patients (n = 20)
- Aged ≥21 years
- Histologically or clinically confirmed stage III-IV lung cancer
- Treatment-naïve (no prior systemic or local therapy for lung cancer)
- Able and willing to provide written informed consent
Age in the registry: 21 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National University Hospital Singapore Coordinator of this site? Confirm its status | Singapore | Singapore | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.